Ranbaxy's Loss Is Dr. Reddy's Gain As Merck Shifts R&D Project For Anti-infectives
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - New Jersey-headquartered pharma giant Merck and Daiichi Sankyo-controlled Ranbaxy have mutually agreed to terminate their five-year discovery research collaboration signed in May 2008. The two allies were to discover and engage in clinical development of new products in the field of anti-infectives, mainly anti-fungal and anti-bacterial drug candidates
You may also be interested in...
Ranbaxy Of India, Merck Of U.S. End Drug-Discovery Agreement
India's Ranbaxy Laboratories and U.S.-based Merck have ended a collaboration aimed at discovering and developing new drugs, as reported in PharmAsia News, Dec. 15
Ranbaxy Of India, Merck Of U.S. End Drug-Discovery Agreement
India's Ranbaxy Laboratories and U.S.-based Merck have ended a collaboration aimed at discovering and developing new drugs, as reported in PharmAsia News, Dec. 15
Ranbaxy's Discovery Unit To Move Into Daiichi Sankyo's Global R&D Structure To Create New Drugs Faster
MUMBAI - Keeping with the "hybrid business model" that it envisioned in taking over India's largest drug maker Ranbaxy in June 2008, Daiichi Sankyo has announced that the New Drug Discovery Research unit of the Indian firm will be transferred to its global R&D structure. The transaction has been approved by India's Department of Scientific and Industrial Research